EGI
VRDN icon

EAM Global Investors’s Viridian Therapeutics VRDN Stock Holding History

EAM Global Investors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-122,864
Closed -$3.13M – 125
2023
Q1 		$3.13M Sell
122,864
-29,042
-19% -$931K 0.88% 76
2022
Q4 		$4.44M Buy
151,906
+73,096
+93% +$1.68M 1.15% 14
2022
Q3 		$1.62M Buy
+78,810
New +$1.42M 0.43% 120

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

EAM Global Investors's VRDN Position: Q2 2023 in Review

EAM Global Investors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 122,864 shares — an estimated $3.13M sold.

EAM Global Investors first reported a position in VRDN in Q3 2022 and held it in 3 quarters. The position peaked at $4.44M in Q4 2022. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • EAM Global Investors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • EAM Global Investors sold 122,864 Viridian Therapeutics shares in Q2 2023, an estimated $3.13M.
  • EAM Global Investors first reported a position in Viridian Therapeutics in Q3 2022 and held it in 3 quarters.
  • EAM Global Investors's Viridian Therapeutics position peaked at $4.44M in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on EAM Global Investors's 13F filing for Q2 2023, filed 11 Aug 2023.